Benefit

Technology Description

Cancer treatment often leaves patients with lasting physical and emotional challenges, and many seek supportive options to improve energy, well‑being, and overall quality of life. There is a growing need for safe, accessible products that complement conventional care without adding financial or medical burden.

Dr. Andrean Burnett is developing a novel synergistic antioxidant formulation designed to support patients during and after cancer therapy. Early laboratory studies demonstrate that the combined formulation exhibits a unique biological effect not seen with individual components alone, suggesting a powerful synergy that selectively impacts cancer cells while remaining safe for healthy tissues. Unlike many experimental therapies, this approach leverages ingredients with established safety records, creating a strong fit for rapid commercialization within the expanding nutraceutical and integrative‑health markets. The platform also offers potential for future product variations built on the same underlying mechanism. Overall, this technology represents a promising opportunity to deliver an accessible, consumer‑friendly product aimed at enhancing quality of life for individuals navigating cancer care.

UIRF Case No. 2026-049

Stage of Development

Early-stage laboratory results demonstrate promising activity across several head and neck cancer cell lines.